Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Ergomed Plc | Netscientific PLC | MaxCyte | ReNeuron Group Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.

 

This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

 

The event is not suitable for people pursuing commercial opportunities.

Ergomed Plc

RSS Portfolio

Ergomed-logo.png


Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries.

Ergomed plc has two complementary businesses:
(1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and
(2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

EPIC: ERGO
Market: AIM
52-week High/Low: 300.00p / 163.10p
Market Cap: 109.30M


View full company profile

MaxCyte

RSS Portfolio

1523368175_Maxcyte.png


We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.

This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.

We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges. To read more click here.

 

EPIC: MXCT
Market: AIM
52-week High/Low: 284.00p / 230.00p
Market Cap: 126.52M


View full company profile

Netscientific PLC

RSS Portfolio

netscientific-logo.png


NetScientific's mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people's lives and society.

NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.

NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.

EPIC: NSCI
Market: AIM
52-week High/Low: 77.00p / 36.00p
Market Cap: 34.96M


View full company profile

ReNeuron Group Plc

RSS Portfolio

reneuron_logo.png


ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron is traded in the NEX Exchange HERE

EPIC: RENE
Market: AIM
52-week High/Low: 220.00p / 1.95p
Market Cap: 25.95M


View full company profile

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use